Literature DB >> 8844118

Cytokine expression in psoriatic skin lesions during PUVA therapy.

A K Olaniran1, B S Baker, D G Paige, J J Garioch, A V Powles, L Fry.   

Abstract

To determine whether an improvement in skin lesions as a result of PUVA therapy may be correlated with changes in cytokine patterns, RT-PCR amplification was used to compare the levels of IL-2, IL-6, IL-8, IL-10, TNF-alpha and IFN-gamma cytokine mRNA expression in serial biopsies from three chronic plaque psoriatic patients. In each case, 3-mm punch biopsies were taken from lesional skin before and during 2-28 days of treatment with PUVA. Total mRNA was extracted from each biopsy, cDNA synthesized, and then amplified by 35 cycles of PCR using cytokine-specific primers. The specificity of the PCR products was confirmed by the Southern blot technique. Substantial levels of specific mRNA for each of the cytokines studied was present in the lesions prior to treatment. In two of the three patients who responded well to PUVA, a reduction in all the cytokines including IL-10 was observed compared with baseline levels. In contrast, PUVA proved to be ineffective in clearing the psoriasis of the third patient whose skin lesions worsened during the course of treatment. This was accompanied by an increase in IFN-gamma but not of the other cytokines investigated, above the pretreatment level. This study showed an association between PUVA-induced resolution and decreases in the levels of various cytokines highly expressed in psoriatic lesions.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8844118     DOI: 10.1007/bf02505228

Source DB:  PubMed          Journal:  Arch Dermatol Res        ISSN: 0340-3696            Impact factor:   3.017


  25 in total

1.  Epidermal T lymphocytes and dendritic cells in chronic plaque psoriasis: the effects of PUVA treatment.

Authors:  B S Baker; A F Swain; C E Griffiths; J N Leonard; L Fry; H Valdimarsson
Journal:  Clin Exp Immunol       Date:  1985-09       Impact factor: 4.330

2.  Upper keratinocytes of psoriatic skin lesions express high levels of NAP-1/IL-8 mRNA in situ.

Authors:  R Gillitzer; R Berger; V Mielke; C Müller; K Wolff; G Stingl
Journal:  J Invest Dermatol       Date:  1991-07       Impact factor: 8.551

3.  Interleukin-6 in the epidermis of patients with psoriasis before and during PUVA treatment.

Authors:  A Oxholm; P Oxholm; B Staberg; K Bendtzen
Journal:  Acta Derm Venereol       Date:  1989       Impact factor: 4.437

4.  A comparison of the stimulatory effects of cytokines on normal and psoriatic keratinocytes in vitro.

Authors:  A K Olaniran; B S Baker; J J Garioch; A V Powles; L Fry
Journal:  Arch Dermatol Res       Date:  1995       Impact factor: 3.017

5.  T cells involved in psoriasis vulgaris belong to the Th1 subset.

Authors:  J F Schlaak; M Buslau; W Jochum; E Hermann; M Girndt; H Gallati; K H Meyer zum Büschenfelde; B Fleischer
Journal:  J Invest Dermatol       Date:  1994-02       Impact factor: 8.551

6.  The cytokine network in lesional and lesion-free psoriatic skin is characterized by a T-helper type 1 cell-mediated response.

Authors:  K Uyemura; M Yamamura; D F Fivenson; R L Modlin; B J Nickoloff
Journal:  J Invest Dermatol       Date:  1993-11       Impact factor: 8.551

7.  Systemic suppression of delayed-type hypersensitivity by supernatants from UV-irradiated keratinocytes. An essential role for keratinocyte-derived IL-10.

Authors:  J M Rivas; S E Ullrich
Journal:  J Immunol       Date:  1992-12-15       Impact factor: 5.422

8.  Flow cytometric quantification of T6-positive cells in psoriatic epidermis after PUVA and methotrexate therapy.

Authors:  J M Gommans; S J van Hezik; B E van Huystee
Journal:  Br J Dermatol       Date:  1987-05       Impact factor: 9.302

9.  GM-CSF, IL-1 alpha, IL-1 beta, IL-6, IL-8, IL-10, ICAM-1 and VCAM-1 gene expression and cytokine production in human duodenal fibroblasts stimulated with lipopolysaccharide, IL-1 alpha and TNF-alpha.

Authors:  G Pang; L Couch; R Batey; R Clancy; A Cripps
Journal:  Clin Exp Immunol       Date:  1994-06       Impact factor: 4.330

10.  Ultraviolet light depletes surface markers of Langerhans cells.

Authors:  W Aberer; G Schuler; G Stingl; H Hönigsmann; K Wolff
Journal:  J Invest Dermatol       Date:  1981-03       Impact factor: 8.551

View more
  7 in total

1.  IL-10 is a key cytokine in psoriasis. Proof of principle by IL-10 therapy: a new therapeutic approach.

Authors:  K Asadullah; W Sterry; K Stephanek; D Jasulaitis; M Leupold; H Audring; H D Volk; W D Döcke
Journal:  J Clin Invest       Date:  1998-02-15       Impact factor: 14.808

2.  CD3+CD56+ NK T cells are significantly decreased in the peripheral blood of patients with psoriasis.

Authors:  A Koreck; A Surányi; B J Szöny; A Farkas; Z Bata-Csörgö; L Kemény; A Dobozy
Journal:  Clin Exp Immunol       Date:  2002-01       Impact factor: 4.330

3.  Anti-scratching behavioral effects of N-stearoyl-phytosphingosine and 4-hydroxysphinganine in mice.

Authors:  Kwon-Ryeol Ryu; Bomi Lee; In-Ah Lee; Sekwan Oh; Dong-Hyun Kim
Journal:  Lipids       Date:  2010-06-29       Impact factor: 1.880

4.  Immunological and histological evaluation of clinical samples from psoriasis patients treated with anti-CD6 itolizumab.

Authors:  Lazaro E Aira; Alejandro López-Requena; Dasha Fuentes; Liset Sánchez; Teresita Pérez; Aleida Urquiza; Heber Bautista; Leopoldina Falcón; Patricia Hernández; Zaima Mazorra
Journal:  MAbs       Date:  2014-03-04       Impact factor: 5.857

5.  Biologics in the management of psoriasis.

Authors:  Jennifer D Bahner; Lauren Y Cao; Neil J Korman
Journal:  Clin Cosmet Investig Dermatol       Date:  2009-07-23

6.  Skin-on-a-chip model simulating inflammation, edema and drug-based treatment.

Authors:  Maierdanjiang Wufuer; GeonHui Lee; Woojune Hur; Byoungjun Jeon; Byung Jun Kim; Tae Hyun Choi; SangHoon Lee
Journal:  Sci Rep       Date:  2016-11-21       Impact factor: 4.379

7.  Evaluation of selected mechanisms of immune tolerance in psoriasis.

Authors:  Agnieszka Owczarczyk-Saczonek; Joanna Czerwińska; Małgorzata Orylska; Waldemar Placek
Journal:  Postepy Dermatol Alergol       Date:  2019-06-19       Impact factor: 1.837

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.